Neurocrine Biosciences Inc. (NBIX)

79.40
NASDAQ : Health Technology
Prev Close 78.18
Day Low/High 77.01 / 80.42
52 Wk Low/High 41.76 / 92.98
Avg Volume 827.40K
Exchange NASDAQ
Shares Outstanding 89.88M
Market Cap 7.03B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Live Audio Webcast Will be on February 15, 2018

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 13

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast Will be on January 8, 2018

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial

Neurocrine Biosciences To Present At The 29th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences To Present At The 29th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast Will be on November 28, 2017

Neurocrine Biosciences To Present At The Jefferies 2017 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2017 London Healthcare Conference

Live Audio Webcast Will be on November 16, 2017

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

AbbVie Announces Positive Phase 3 Extension Study Data For Investigational Oral Treatment Elagolix For Management Of Endometriosis With Associated Pain

AbbVie Announces Positive Phase 3 Extension Study Data For Investigational Oral Treatment Elagolix For Management Of Endometriosis With Associated Pain

- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse

Neurocrine Biosciences To Present At The Credit Suisse 26th Annual Healthcare Conference

Neurocrine Biosciences To Present At The Credit Suisse 26th Annual Healthcare Conference

Live Audio Webcast Will be on November 8, 2017

AbbVie Receives U.S. FDA Priority Review For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

AbbVie Receives U.S. FDA Priority Review For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

- FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease

Neurocrine Initiates Phase IIb Clinical Study Of Once-daily INGREZZA® In Children And Adolescents With Tourette Syndrome

Neurocrine Initiates Phase IIb Clinical Study Of Once-daily INGREZZA® In Children And Adolescents With Tourette Syndrome

12-Week T-Force GOLD Study to Assess the Safety, Tolerability, Efficacy and Optimal Dose of INGREZZA in Pediatric Patients

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2017 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2017 Results

Conference Call and Webcast Scheduled for November 1, 2017

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

TheStreet Quant Rating: D+ (Sell)